Report Sections

See All Reports

  • HP:0002725: Systemic lupus erythematosus
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002725: Systemic lupus erythematosus

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO

    Correlated Drug Terms (9)

    Name (Synonyms) Correlation
    drug576 C21 Wiki 0.45
    drug661 COVID-19 infection Wiki 0.45
    drug560 Bromhexine 8 MG Wiki 0.45
    Name (Synonyms) Correlation
    drug2744 Questionnaire by phone call Wiki 0.45
    drug567 Bucillamine Wiki 0.32
    drug3395 Telemedicine Wiki 0.22
    drug3212 Standard care Wiki 0.16
    drug1538 Hydroxychloroquine Sulfate Wiki 0.13
    drug2505 Placebo Wiki 0.04

    Correlated MeSH Terms (12)

    Name (Synonyms) Correlation
    D008180 Lupus Erythematosus, Systemic NIH 0.91
    D001167 Arteritis NIH 0.63
    D015535 Arthritis, Psoriatic NIH 0.52
    Name (Synonyms) Correlation
    D011111 Polymyalgia Rheumatica NIH 0.52
    D013700 Giant Cell Arteritis NIH 0.52
    D025241 Spondylarthritis NIH 0.45
    D012859 Sjogren's Syndrome NIH 0.45
    D001327 Autoimmune Diseases NIH 0.40
    D001168 Arthritis NIH 0.35
    D003095 Collagen Diseases NIH 0.18
    D012216 Rheumatic Diseases NIH 0.16
    D001172 Arthritis, Rheumatoid NIH 0.13

    Correlated HPO Terms (4)

    Name (Synonyms) Correlation
    HP:0012089 Arteritis HPO 0.63
    HP:0002960 Autoimmunity HPO 0.45
    HP:0001369 Arthritis HPO 0.39
    Name (Synonyms) Correlation
    HP:0001370 Rheumatoid arthritis HPO 0.16

    Clinical Trials

    Navigate: Correlations   HPO

    There are 5 clinical trials

    1 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

    The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

    1. Rheumatoid Arthritis
    2. Psoriatic Arthritis
    3. Axial Spondyloarthritis
    4. Systemic Lupus Erythematosus
    5. Giant Cell Arteritis
    1. Other: COVID-19 infection
    MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases
    HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus

    Primary Outcomes

    Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease

    Measure: Disease activity

    Time: Last registration of disease activity in the medical journal before admission/inclusion

    Secondary Outcomes

    Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.

    Measure: Immune modulating treatments

    Time: Current immune modulating treatments at admission/inclusion

    Description: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups

    Measure: Biomarkers

    Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1
    2 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease

    This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.

    1. SARS-CoV-2
    2. Systemic Lupus Erythematosus
    3. Rheumatoid Arthritis
    4. Sjogren's Syndrome
    5. Psoriatic Arthritis
    1. Other: Questionnaire by phone call
    MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
    HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus

    Primary Outcomes

    Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.

    Measure: Adjusted Odds Ratio

    Time: 4 months after inclusion
    3 Manifestations Related to Covid-19 in Patients With Systemic Lupus Erythematosus

    The Covid-19 pandemic is a major public health issue. Potential treatments are essential to control the infection. Hydroxychlorquine is currently tested in several clinical trials to evaluate its efficiency.The objective of this study was to evaluate the symptoms related to COVID-19 occuring in patients with systemic lupus erythematosus (SLE)

    1. Systemic Lupus Erythematosus
    2. Covid-19
    MeSH:Lupus Erythematosus, Systemic
    HPO:Systemic lupus erythematosus

    Primary Outcomes

    Description: prevalence and severity of Covid-19 infection in patients with SLE

    Measure: prevalence and severity of Covid-19 infection in patients with SLE

    Time: 1 day

    Secondary Outcomes

    Description: prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine

    Measure: prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine

    Time: 1 day
    4 Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus ("TeleSLE") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial

    Background Patients with systemic lupus erythematosus (SLE) might be more susceptible to Covid-19 due to the underlying disease, co-morbidities and the use of immunosuppressive drugs. The investigators hypothesize that telemedicine (TM) can be an effective mode of health-care delivery minimizing the risk of SARS-CoV-2 exposure, while maintaining disease control in these patients. Objectives The primary aim of this study is to evaluate the effectiveness to achieve remission or lupus low disease activity state (LLDAS) using TM delivered care compared to conventional in-person outpatient follow-up in SLE. The secondary objectives are to compare the patient reported outcomes and cost between the two modes of health care delivery. Study design This is a 12-months single centered pragmatic randomized controlled study. A total of 150 enrolled patients with SLE being followed at the Prince of Wales Hospital rheumatology clinics will be randomized to either TM (TM group) or standard care (SC group) in a 1:1 ratio. Patients in the TM group will receive scheduled follow-ups via videoconferencing using a custom-made mobile app. SC group patients will continue conventional standard in-person outpatient care. The disease and patient reported outcomes as well as the health care related costs will be compared. Expected outcomes Data from this study will support the notion that TM based care is as effective as conventional in-person care in achieving disease remission or LLDAS, as well as addressing psychosocial implications to ensure the best possible care for our patients in a cost-effective manner during this pandemic.

    1. SLE
    1. Other: Telemedicine
    2. Other: Standard care
    MeSH:Lupus Erythematosus, Systemic
    HPO:Systemic lupus erythematosus

    Primary Outcomes

    Measure: The percentage of patients in remission or LLDAS at one year.

    Time: 1 year

    Secondary Outcomes

    Measure: Direct and indirect costs after one year.

    Time: 1 year

    Description: LupusQoL evaluates 8 domains including physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Questionnaire has a 5-point Likert response format (0=all the time, 1=most of the time, 2=a good bit of the time, 3=occasionally, and 4=never). Higher score means better quality of life.

    Measure: The change of Lupus Quality of Life (LupusQoL) at one year.

    Time: 1 year

    Description: They are in a 5-point Likert response format (0=strongly disagree, 1=disagree, 2=neutral, 3=agree, and 4=strongly agree). Higher score means more confident and satisfied.

    Measure: Patient confidence and satisfaction score at one year.

    Time: 1 year

    Measure: Rates of adverse reaction and severe adverse reaction, including contracting COVID-19 infection, after one year.

    Time: 1 year

    Measure: Numbers of clinic visits, hospitalization, overall in-person hospital visits in one year.

    Time: 1 year

    Description: HAQ-DI covers various common daily activities to assess disability.It consists of 8 questions. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). Higher score means higher disability.

    Measure: The change of (Health Assessment Questionnaire Disability Index HAQ-DI) at one year.

    Time: 1 year

    Description: HADS was developed to assess anxiety and depression in medical patients. Each domain has 7 items. Each item are answered by the patient on a four point (0-3) response category so the possible scores ranged from 0 to 21 for anxiety and 0 to 21 for depression. Higher score means more likely the patient has anxiety or depression.

    Measure: The change of (Hospital Anxiety and Depression Scale) HADS at one year.

    Time: 1 year
    5 Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe

    The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

    1. COVID-19
    2. Systemic Lupus Erythematosus
    3. Sjogren's Syndrome
    4. Axial Spondyloarthritis
    5. Rheumatoid Arthritis
    6. Giant Cell Arteritis
    MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases
    HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus

    Primary Outcomes

    Description: ELISA tests for COVID-19 antibodies

    Measure: COVID-19 seroconversion

    Time: 1 day, during routine blood collection

    Description: Case report form filled by the health professional

    Measure: COVID-19 infection

    Time: During medical visit or phone consultation, up to 2 hours

    Secondary Outcomes

    Description: Descriptive analysis for each disease's rate

    Measure: Seroconversion rate by disease

    Time: 1 day, during routine blood collection

    Description: Descriptive analysis for each country's rate

    Measure: Penetration across Europe

    Time: 1 day, during routine blood collection

    Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.

    Measure: COVID-19 severity

    Time: During medical visit, up to 1 hour

    Description: Descriptive analysis for overall and COVID-19-linked mortality rates

    Measure: COVID-19 mortality rate

    Time: During contact with family members, up to 1 hour

    Description: Case report form filled by the health professional

    Measure: COVID-19 impact on immunomodulatory treatment

    Time: During medical visit, up to 1 hour

    Description: Case report form filled by the patient

    Measure: Patient-reported flares

    Time: During medical visit, up to 1 hour

    Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.

    Measure: Patient's fears towards COVID-19

    Time: During medical visit, up to 1 hour

    Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.

    Measure: Patient's beliefs in their medicines towards COVID-19

    Time: During medical visit, up to 1 hour

    HPO Nodes


    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  


    4,180 reports on interventions/drugs


    691 reports on MeSH terms


    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook